[go: up one dir, main page]

WO2003062376A3 - Molecules for diagnostics and therapeutics - Google Patents

Molecules for diagnostics and therapeutics Download PDF

Info

Publication number
WO2003062376A3
WO2003062376A3 PCT/US2003/001096 US0301096W WO03062376A3 WO 2003062376 A3 WO2003062376 A3 WO 2003062376A3 US 0301096 W US0301096 W US 0301096W WO 03062376 A3 WO03062376 A3 WO 03062376A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
provides
therapeutics
diagnostics
diagnostic assays
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/001096
Other languages
French (fr)
Other versions
WO2003062376A2 (en
Inventor
Anissa L Jones
Christopher R Dahl
Darryl Gietzen
Joyce Chinn
Gerard E Dufour
Jennifer L Jackson
Jimmy Y Yu
Olivia Tuason
Pierre E Yap
Stefan R Amshey
Tam C Dam
Tommy F Liu
Jr Edward H Gerstin
Careyna H Peralta
Samantha A Lewis
Alice Chen
Rakesh Marwaha
Ruth Y Lan
Michael E Urashka
Sreenivasa R Kristnam
Vijaykumar Kolluru
Iqbal S Panesar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to AU2003210518A priority Critical patent/AU2003210518A1/en
Publication of WO2003062376A2 publication Critical patent/WO2003062376A2/en
Publication of WO2003062376A3 publication Critical patent/WO2003062376A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.
PCT/US2003/001096 2002-01-16 2003-01-13 Molecules for diagnostics and therapeutics Ceased WO2003062376A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003210518A AU2003210518A1 (en) 2002-01-16 2003-01-13 Molecules for diagnostics and therapeutics

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34938402P 2002-01-16 2002-01-16
US60/349,384 2002-01-16
US34941302P 2002-01-17 2002-01-17
US34994602P 2002-01-17 2002-01-17
US60/349,946 2002-01-17
US60/349,413 2002-01-17

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10510643 A-371-Of-International 2003-04-07
US10/510,643 A-371-Of-International US7906145B2 (en) 2002-04-09 2003-04-07 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US13/014,137 Continuation US10004693B2 (en) 2002-04-09 2011-01-26 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)

Publications (2)

Publication Number Publication Date
WO2003062376A2 WO2003062376A2 (en) 2003-07-31
WO2003062376A3 true WO2003062376A3 (en) 2003-12-31

Family

ID=27617579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001096 Ceased WO2003062376A2 (en) 2002-01-16 2003-01-13 Molecules for diagnostics and therapeutics

Country Status (2)

Country Link
AU (1) AU2003210518A1 (en)
WO (1) WO2003062376A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20090081226A1 (en) * 2004-12-17 2009-03-26 Inserm (Institut National De La Sante Et De La Recherche Medicle) Soluble HLA-E Molecules And Their Use For Diagnosing And Treating Pathologies
FI20050011L (en) * 2005-01-05 2006-07-06 Jurilab Ltd Oy Method and test kit for detecting the risk of type 2 diabetes mellitus
ATE497389T1 (en) 2005-08-19 2011-02-15 Univ Duke PARACCRINE FACTOR H12 OBTAINED FROM STEM CELLS FOR USE IN REDUCING CELL DEATH OR FOR REPAIR OF TISSUE
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 substituted nucleotide analogs
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORI K. ET AL.: "MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 45, 6 November 1998 (1998-11-06), pages 29794 - 29800, XP002971615 *
SULSTON ET AL.: "Toward a complete human genome sequence", GENOME RESEARCH, vol. 8, November 1998 (1998-11-01), pages 1097 - 1108, XP002181292 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Also Published As

Publication number Publication date
AU2003210518A1 (en) 2003-09-02
WO2003062376A2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
WO2004023973A3 (en) Molecules for diagnostics and therapeutics
WO2002097031A3 (en) Molecules for diagnostics and therapeutics
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
WO2002083876A3 (en) Secretory molecules
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2006056480A3 (en) Means and methods for detecting methylated dna
WO2008073914A3 (en) Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
WO2007054520A3 (en) Methods for the identification of microrna and their applications in research and human health
WO2002046228A3 (en) Receptor for b. anthracis toxin
WO2003062376A3 (en) Molecules for diagnostics and therapeutics
WO2002040715A3 (en) Molecules for disease detection and treatment
WO2002020756A3 (en) Secretory molecules
WO2001062927A3 (en) Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
WO2008124170A3 (en) SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES
WO2003062385A3 (en) Secretory molecules
WO2004100886A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
WO2001062922A3 (en) Polypeptides and corresponding molecules for disease detection and treatment
WO2002020754A3 (en) Molecules for diagnostics and therapeutics
WO2005069854A3 (en) Methods and materials relating to novel c1q domain-containing polypeptides and polynucleotides
WO2002055738A3 (en) Molecules for disease detection and treatment
WO2001062918A3 (en) Secretory polypeptides and corresponding polynucleotides
WO2002079473A3 (en) Molecules for diagnostics and therapeutics
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
WO2001021836A3 (en) Molecules for diagnostics and therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP